Lo Loestrin Fe Kit
Product Images NDC 0430-0420

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Lo Loestrin Fe (NDC 0430-0420). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Allergan, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

The Structural Formula For Ethinyl Estradiol Is [19-norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17)-]. (Lo Loestrin Fe 01)

The Structural Formula For Ethinyl Estradiol Is [19-norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17)-]. (Lo Loestrin Fe 01)
FDA Label Image

The Structural Formula For Norethindrone Acetate Is [19-norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17)-]. (Lo Loestrin Fe 02)

The Structural Formula For Norethindrone Acetate Is [19-norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17)-]. (Lo Loestrin Fe 02)
FDA Label Image

Figure 1. Mean (± Sd) Plasma Ethinyl Estradiol Concentration Versus Time Profiles Following Single- And Multiple-dose Oral Administration Of Lo Loestrin Fe To Healthy Female Volunteers (n = 15) (Lo Loestrin Fe 03)

Figure 1. Mean (± Sd) Plasma Ethinyl Estradiol Concentration Versus Time Profiles Following Single- And Multiple-dose Oral Administration Of Lo Loestrin Fe To Healthy Female Volunteers (n = 15) (Lo Loestrin Fe 03)
FDA Label Image

Figure 2. Mean (± Sd) Plasma Norethindrone Concentration Versus Time Profiles Following Single- And Multiple-dose Oral Administration Of Lo Loestrin Fe To Healthy Female Volunteers (n = 15) (Lo Loestrin Fe 04)

Figure 2. Mean (± Sd) Plasma Norethindrone Concentration Versus Time Profiles Following Single- And Multiple-dose Oral Administration Of Lo Loestrin Fe To Healthy Female Volunteers (n = 15) (Lo Loestrin Fe 04)
FDA Label Image

The Following Chart Shows The Chance Of Getting Pregnant For Women Who Use Different Methods Of Birth Control. Each Box On The Chart Contains A List Of Birth Control Methods That Are Similar In Effectiveness. The Most Effective Methods Are At The Top Of The Chart. The Box On The Bottom Of The Chart Shows The Chance Of Getting Pregnant For Women Who Do Not Use Birth Control And Are Trying To Get Pregnant. (Lo Loestrin Fe 05)

The Following Chart Shows The Chance Of Getting Pregnant For Women Who Use Different Methods Of Birth Control. Each Box On The Chart Contains A List Of Birth Control Methods That Are Similar In Effectiveness. The Most Effective Methods Are At The Top Of The Chart. The Box On The Bottom Of The Chart Shows The Chance Of Getting Pregnant For Women Who Do Not Use Birth Control And Are Trying To Get Pregnant. (Lo Loestrin Fe 05)
FDA Label Image

2. Look At Your Pill Pack: The Lo Loestrin Fe Pill Pack Has 24 "active" Blue Pills (with Hormones) And 2 “active” White Pills (with Hormones) For Weeks 1, 2, 3 And Part Of Week 4. The Pill Pack Also Has 2 "reminder" Brown Pills (without Hormones) For The Last Part Of Week 4. (Lo Loestrin Fe 06)

2. Look At Your Pill Pack: The Lo Loestrin Fe Pill Pack Has 24 "active" Blue Pills (with Hormones) And 2 “active” White Pills (with Hormones) For Weeks 1, 2, 3 And Part Of Week 4. The Pill Pack Also Has 2 "reminder" Brown Pills (without Hormones) For The Last Part Of Week 4. (Lo Loestrin Fe 06)
The text contains information about contraception methods and their effectiveness in preventing pregnancies. The vaginal ring with hormones and condoms, diaphragm, and spermicide are mentioned alongside withdrawal as methods of contraception. The text provides statistics on the number of pregnancies per 100 women in one year, with fewer than 1 pregnancy per 100 women with the vaginal ring with hormones, and 10 to 20 pregnancies per 100 women with other methods listed. However, the last sentence appears to be incomplete or unclear, possibly due to errors, and reads as "85 or more pregnancies per 100 women or pregnancies + Mobith ol." Therefore, the description based on this text is: Information about several types of contraception methods and their effectiveness in preventing pregnancies, with varying rates of success.*
FDA Label Image

Principal Display Panelndc 0430-0420-14lo Loestrin Fe26 Days Of Active Therapy5 Blister Cards Of 28 Tablets Eachrx Only (Lo Loestrin Fe 07)

Principal Display Panelndc 0430-0420-14lo Loestrin Fe26 Days Of Active Therapy5 Blister Cards Of 28 Tablets Eachrx Only (Lo Loestrin Fe 07)
FDA Label Image

Principal Display Panelndc 0430-0420-95lo Loestrin Fe26 Days Of Active Therapy1 Blister Card Of 28 Tablets Eachrx Only (Lo Loestrin Fe 08)

Principal Display Panelndc 0430-0420-95lo Loestrin Fe26 Days Of Active Therapy1 Blister Card Of 28 Tablets Eachrx Only (Lo Loestrin Fe 08)
FDA Label Image

Lo Loestrin Fe 09

Lo Loestrin Fe 09
LoLoestrn Fe is a medication that provides 26 days of active therapy. It is marketed by Allergan and is available for medical use.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.